Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JonesTrading Downgrades Concert Pharma to Hold

JonesTrading Downgrades Concert Pharma to Hold

JonesTrading analyst Sean Kim downgrades Concert Pharma (NASDAQ:CNCE) from Buy to Hold.

byBenzinga Newsdesk

January 20, 2023

1 minute read

JonesTrading analyst Sean Kim downgrades Concert Pharma (NASDAQ:CNCE) from Buy to Hold.

Wells Fargo Maintains Overweight on TELUS Intl, Lowers Price Target to $27

By Benzinga Newsdesk

January 9, 11:01 AM

Wells Fargo analyst Jeff Cantwell maintains TELUS Intl (NYSE:TIXT) with a Overweight and lowers the price target from $30 to $27.

TIXT

Labcorp Narrows FY23 EPS Outlook to $16.25 – $17.75 ($16.00 – $18.00 Prior) Vs, $17.30 Estimate, Revenue Growth 1.5% – 4% (1% – 4% prior)

By Benzinga Newsdesk

April 25, 6:57 AM

Labcorp is updating 2023 full year guidance to reflect its first quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of March 31, 2023, for the remainder of

Analyst Ratings

11 Analysts Have This to Say About Essex Property Trust

By Benzinga Insights

October 7, 10:03 AM

Analysts have provided the following ratings for Essex Property Trust (NYSE:ESS) within the last quarter:

ESS

Nvidia’s Earnings Would Be Tell-Tale For US Stock Market Rally: ‘If They Do Well…’

By Benzinga Neuro

May 22, 9:55 AM

The company's influence on broader markets has grown due to its leading position in artificial intelligence.

NVDA

JonesTrading Downgrades Concert Pharma to Hold

Related Posts

Wells Fargo Maintains Overweight on TELUS Intl, Lowers Price Target to $27

Labcorp Narrows FY23 EPS Outlook to $16.25 – $17.75 ($16.00 – $18.00 Prior) Vs, $17.30 Estimate, Revenue Growth 1.5% – 4% (1% – 4% prior)

11 Analysts Have This to Say About Essex Property Trust

Nvidia’s Earnings Would Be Tell-Tale For US Stock Market Rally: ‘If They Do Well…’